Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

$153.23 -0.61 (-0.39%)

Closing price 03:59 PM Eastern

Extended Trading

$153.50 +0.26 (+0.17%)

As of 07:45 PM Eastern

Compare

Becton, Dickinson and Company - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 16 Analyst Ratings

Sell
1

Hold
8

Buy
7

Based on 16 Wall Street analysts who have issued ratings for Becton, Dickinson and Company in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 1 has given a sell rating, 8 have given a hold rating, and 7 have given a buy rating for BDX.

Consensus Price Target

$180.29
17.65% Upside

According to the 16 analysts' twelve-month price targets for Becton, Dickinson and Company, the average price target is $180.29. The highest price target for BDX is $232.00, while the lowest price target for BDX is $150.00. The average price target represents a forecasted upside of 17.65% from the current price of $153.23.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for BDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Becton, Dickinson and Company and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BDX Analyst Ratings Over Time

Type	Current Forecast 7/22/25 to 7/22/26	1 Month Ago 6/22/25 to 6/22/26	3 Months Ago 4/23/25 to 4/23/26	1 Year Ago 7/22/24 to 7/22/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	4 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	11 Hold rating(s)	7 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$180.29	$181.00	$189.08	$219.22
Forecasted Upside	17.65% Upside	28.94% Upside	22.02% Upside	20.79% Upside
Consensus Rating	Hold	Hold	Hold	Hold

BDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Becton, Dickinson and Company Stock vs. The Competition

Type	Becton, Dickinson and Company	Medical Companies	Broader Market
Consensus Rating Score	2.38	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	18.14% Upside	891.53% Upside	14.29% Upside
News Sentiment Rating	Positive News See Recent BDX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/6/2026	Evercore 3 of 5 stars		Set Target		$180.00	+15.86%
6/12/2026	Bank of America 4 of 5 stars		Lower Target		$177.00 ➝ $170.00	+15.95%
5/27/2026	The Goldman Sachs Group 3 of 5 stars	David Roman Not Rated	Lower Target	Neutral	$156.00 ➝ $150.00	+2.55%
5/11/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold (C-) ➝ Sell (D+)
5/11/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$202.00 ➝ $204.00	+36.69%
5/8/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lawrence Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$157.00 ➝ $161.00	+5.35%
5/7/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$215.00 ➝ $175.00	+14.51%
5/4/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Jennings Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$189.00 ➝ $163.00	+8.66%
4/17/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Bednar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$170.00 ➝ $159.00	+2.65%
4/14/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$175.00	+12.64%
TSM just handed Trump's secretive AI project $100 billion (Ad) Taiwan Semiconductor just committed another $100 billion to U.S. chip manufacturing - on top of $165 billion already pledged. Louis Navellier, who manages a $1.1 billion portfolio including $358 million in AI stocks, says this isn't about tariffs. Navellier believes TSM's move is smart money positioning ahead of a government AI supercomputing project he calls Golden Dawn - built at the same Tennessee site that housed the Manhattan Project. S&P 500 profits are tracking near 24% growth this quarter, with AI and chip demand leading the way. See Navellier's free presentation, including the ticker he's watching
4/10/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
3/23/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$230.00 ➝ $180.00	+15.17%
2/10/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$220.00 ➝ $190.00	+10.70%
2/10/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanna Wiensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$233.00 ➝ $232.00	+36.22%
2/10/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$190.00 ➝ $175.00	+4.89%
12/2/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$197.00 ➝ $210.00	+9.45%
5/2/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/1/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Weinstein Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:51 PM ET.

Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, July 22, 2026. Please send any questions or comments about these Becton, Dickinson and Company pros and cons to contact@marketbeat.com.

Becton, Dickinson and Company
Bull Case

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

The company has demonstrated a solid return on equity of over 15%, indicating effective management and profitability.
Recent revenue growth of approximately 5.2% year-over-year suggests a positive trend in sales and market demand for its medical products.
Becton, Dickinson and Company has set an earnings per share (EPS) guidance for FY 2026 between 12.520 and 12.720, which reflects confidence in future profitability.
The current stock price is around $145, which may present a buying opportunity for investors looking for value in the healthcare sector.
The company has a history of paying dividends, with a recent quarterly dividend of $1.05 per share, translating to an annualized yield of approximately 2.8%, appealing to income-focused investors.

Becton, Dickinson and Company
Bear Case

Investors should be bearish about investing in Becton, Dickinson and Company for these reasons:

The company's dividend payout ratio is currently over 106%, which indicates that it is paying out more in dividends than it is earning, raising concerns about sustainability.
Insider selling activity has been noted, with executives selling shares, which could signal a lack of confidence in the company's short-term performance.
Analysts have mixed ratings on the stock, with several price target reductions, suggesting uncertainty about future growth prospects.
Despite revenue growth, the net margin is relatively low at around 5.3%, which may limit profitability and financial flexibility.
Market volatility and economic conditions can impact the healthcare sector, potentially affecting Becton, Dickinson and Company's performance and stock price.

BDX Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Becton, Dickinson and Company is $180.29, with a high forecast of $232.00 and a low forecast of $150.00.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and Company in the last twelve months. There is currently 1 sell rating, 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BDX, but not buy additional shares or sell existing shares.

According to analysts, Becton, Dickinson and Company's stock has a predicted upside of 17.65% based on their 12-month stock forecasts.

Over the previous 90 days, Becton, Dickinson and Company's stock had 1 downgrade by analysts.

Becton, Dickinson and Company has been rated by research analysts at Bank of America, Barclays, Evercore, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Becton, Dickinson and Company more than other "medical" companies. The consensus rating score for Becton, Dickinson and Company is 2.38 while the average consensus rating score for "medical" companies is 2.29. Learn more on how BDX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Becton, Dickinson and Company Recommendations

This page (NYSE:BDX) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

Becton, Dickinson and Company - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BDX Analyst Ratings Over Time

BDX Analyst Recommendations By Month

BDX Price Targets by Month

Becton, Dickinson and Company Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

Becton, Dickinson and Company
Bull Case

Becton, Dickinson and Company
Bear Case

BDX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Becton, Dickinson and Company Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

Becton, Dickinson and Company - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BDX Analyst Ratings Over Time

BDX Analyst Recommendations By Month

BDX Price Targets by Month

Becton, Dickinson and Company Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

Becton, Dickinson and Company Bull Case

Becton, Dickinson and Company Bear Case

BDX Forecast - Frequently Asked Questions

What is Becton, Dickinson and Company's forecast for 2026?

Should I buy or sell Becton, Dickinson and Company stock right now?

Does Becton, Dickinson and Company's stock price have much upside?

Has Becton, Dickinson and Company been downgraded by Wall Street analysts recently?

What analysts cover Becton, Dickinson and Company?

Do Wall Street analysts like Becton, Dickinson and Company more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Becton, Dickinson and Company Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Becton, Dickinson and Company
Bull Case

Becton, Dickinson and Company
Bear Case